Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

LGND 89.67
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Related articles »  
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Stock a Sell after Jason ...
The insider Jason Aryeh who is director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 89.23 +2.45 2.82% sold 9,240 shares of the public firm having a market value of $807,047 USD at an average $87.3 per share.
Ligand Pharmaceuticals Inc (LGND) Insider Selling : Jason Aryeh Sells 9240 ...  Money Flow Index
Active Watch List: Advaxis, Inc. (NASDAQ:ADXS), Ligand Pharmaceuticals ...  Stock Transcript
Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Names ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the appointment of Melanie J. Herman as interim Chief Financial Officer, effective May 21st.
Ligand Pharmaceuticals Inc.: Ligand Names Melanie J. Herman Interim Chief ...  The Wall Street Transcript
Ligand Pharma (LGND) Names Interim Chief Financial Officer
Craig Hallum Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Inc. logo Craig Hallum restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND) in a report issued on Saturday.
Ligand Pharmaceuticals Given Buy Rating at Craig Hallum (LGND)  WKRB News
Active Stocks to Watch: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ...  Stock Transcript
Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc Acquires ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA for $4 million in cash.
Ligand Pharmaceuticals (LGND) John L. Higgins on Q1 2015 Results - Earnings ...  Seeking Alpha
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs ...  MarketWatch
Stock Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Partner TG ...
Ligand Pharmaceuticals Incorporated Inc. (NASDAQ:LGND) partner TG Therapeutics, Inc.(NASDAQ:TGTX) announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4 inhibitor ...
Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc Partner Viking ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) partner Viking Therapeutics Inc (NASDAQ:VKTX) announced that it has priced its initial public offering of 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share ...
Ligand Pharma Partner Viking Therapeutics Prices IPO At $8.00/shr - Quick Facts  RTT News
Ligand Pharmaceuticals Inc.: Ligand Partner Viking Therapeutics Announces ...  The Wall Street Transcript
Why Ligand Pharmaceuticals Inc Just Disclosed Huge New Viking Therapeutics ...
Per Ligand Pharmaceuticals Inc's filing, the filler now owns 49.8% of the company, holding 4,552,859 shares. Viking Therapeutics Inc (NASDAQ:VKTX) is a newly disclosed equity position and the filing was required due to activity on May 4, 2015.
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga's #PreMarket Prep to talk about why he thinks ...
Related articles »  
Recent Research Analysts' Ratings Changes for Ligand Pharmaceuticals (LGND)
Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded down 1.01% on Tuesday, hitting $86.93. The stock had a trading volume of 257,548 shares.
Brokerage Firm Focus: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)  Markets Daily
Active Stocks: Windstream Holdings, Inc. (NASDAQ:WIN), Peregrine ...  Stock Transcript